Showing 3871-3880 of 5910 results for "".
- Ocugen Reports Positive Preliminary Data from OCU410 Trial for Geographic Atrophyhttps://modernod.com/news/ocugen-reports-positive-preliminary-data-from-ocu410-trial-for-geographic-atrophy/2482550/Ocugen announced encouraging preliminary results from the phase 1 portion of its phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The trial, which includes nine patients across three dose cohorts, revealed promis
- Samsung Bioepis and Biogen Announce EC Approval of Eylea Biosimilar Opuvizhttps://modernod.com/news/samsung-bioepis-and-biogen-announce-ec-approval-of-eylea-biosimilar-opuviz/2482545/Samsung Bioepis and Biogen jointly announced that the European Commission (EC) has granted approval for Opuviz 40 mg/mL for injection in a vial. The biosimilar, also known as SB15, references the established treatment Eylea (aflibercept) and was developed by Samsung Bioepis. T
- Eyenovia's Late-Stage Pediatric Myopia Treatment Fails to Meet Primary Endpointhttps://modernod.com/news/eyenovias-late-stage-pediatric-myopia-treatment-fails-to-meet-primary-endpoint/2482544/Eyenovia announced that its phase 3 CHAPERONE study failed to meet its primary endpoint. The study was investigating Eyenovia’s proprietary drug-device combination, using low-dose atropine dispensed through the company's Optejet platform, as a potential treatment for pediatric
- Atsena and Nippon Shinyaku Enter Strategic Collaboration for ATSN-101 Advancementhttps://modernod.com/news/atsena-therapeutics-and-nippon-shinyaku-enter-strategic-collaboration-for-atsn-101-advancement/2482542/Atsena Therapeutics has entered into an exclusive licensing agreement with Nippon Shinyaku for the commercialization of investigational gene therapy ATSN-101 for Leber congenital amaurosis. Atsena's ATSN-101 is a subretinal AAV5 gene therapy undergoing evaluatio
- Bausch + Lomb’s Recycling Programs Collect Over 94 Million Units of Eye Care Waste in the UShttps://modernod.com/news/bausch-lombs-recycling-programs-collect-over-94-million-units-of-eye-care-waste-in-the-us/2482541/Bausch + Lomb announced a milestone in its sustainability efforts—the company's exclusive recycling initiatives, ONE by ONE Recycling and Biotrue Eye Care Recycling programs, have successfully collected a total of 94,119,275 units of used contact lenses, eye care, and lens care material
- Ocular Therapeutix Names Namrata Saroj as Chief Business Officerhttps://modernod.com/news/ocular-therapeutix-names-namrata-saroj-as-chief-business-officer/2482536/Ocular Therapeutix announced that Namrata Saroj, OD, has joined the company as Chief Business Officer (CBO). Dr. Saroj, who has been consulting with Ocular since February 2024, brings extensive experience in clinical development and commercialization in ophthalmology. She cont
- Konan Medical USA Launches objectiveFIELD Visual Field Analyzerhttps://modernod.com/news/konan-medical-usa-launches-objectivefield-visual-field-analyzer/2482534/Konan Medical USA announced the commercial launch of its objectiveFIELD (OFA) visual field analyzer. The OFA is an objective visual field analyzer designed to detect visual field abnormalities using pupillary responses. According to Konan Medical, unlike traditional subjectiv
- AlloVir and Kalaris Announce Merger to Create Company Focused on Retina Diseasehttps://modernod.com/news/allovir-and-kalaris-therapeutics-announce-agreement-for-transformational-merger-to-create-company-focused-on-diseases-of-the-retina/2482532/AlloVir announced that it has entered into a definitive merger agreement to combine with Kalaris Therapeutics in an all-stock transaction. "On behalf of the AlloVir board, I am thrilled that we have entered into this transformational merger agreement with Kalaris,”
- Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2https://modernod.com/news/neurotech-provides-update-on-bla-for-nt-501-as-a-treatment-for-macular-telangiectasia-type-2/2482531/Neurotech Pharmaceuticals announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date by 3 months to allow time required for the FDA to review additional data provided by the company in response to recent requests from the FDA. Originally set for December 17
- Harrow Partners with Asembia to Create Digital Services and Hub Support for Harrow’s Branded Eye Care Productshttps://modernod.com/news/harrow-partners-with-asembia-to-enhance-provider-and-patient-experience-through-nationwide-digital-services-and-hub-support-for-harrows-branded-eye-care-products/2482530/Harrow announced the nationwide launch of a new digital patient access solution in collaboration with Asembia. This multi-year partnership is designed to expand access to Harrow’s ophthalmic branded products, including Flarex, Ilevro, Maxidex, Maxitrol, Natacyn, Nevanac, Tobradex ST, Verkaz